Vertex Pharmaceuticals Inc (VRTX)
Health Care ยท Pharmaceutical Preparations
Vertex Pharmaceuticals Inc (VRTX) is listed on Nasdaq, where its shares have traded since July 31, 1991. SentiSense covers Vertex Pharmaceuticals Inc in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Reshma Kewalramani is its chief executive officer. The company reports 6,400 employees, and its corporate website is www.vrtx.com.
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).
Latest reported results
Vertex Pharmaceuticals Incorporated reported revenue of $3.33 billion for Q2 FY2026, up 12.5% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 1,722 institutions reported holding VRTX, with 239.6 million shares worth $118.8 billion in aggregate. The largest reported holders were Capital Group, BlackRock and Vanguard. Of the 5 largest reported holders, 3 added shares and 2 reduced their positions during the quarter.
More on VRTX
- VRTX sentiment: whether news and social coverage of Vertex Pharmaceuticals Inc leans bullish or bearish, and the stories driving it.
- VRTX ownership: all 1,722 reporting institutions, plus insider and congressional trades.
- VRTX financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
SentiSense also tracks daily options readings for Vertex Pharmaceuticals Inc: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Vertex Pharmaceuticals Inc do?
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases.
What sector is VRTX in?
SentiSense classifies Vertex Pharmaceuticals Inc in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does VRTX stock trade?
Vertex Pharmaceuticals Inc (VRTX) is listed on Nasdaq, where its shares have traded since July 31, 1991.
Who is the CEO of Vertex Pharmaceuticals Inc?
Reshma Kewalramani is the chief executive officer of Vertex Pharmaceuticals Inc.